The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome

J. B. Eisengart; K. E. King; E. G. Shapiro; C. B. Whitley; J. Muenzer

doi:10.1016/j.ymgmr.2019.100549

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome

J. B. Eisengart, K. E. King, E. G. Shapiro, C. B. Whitley, J. Muenzer

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.

Original language	English (US)
Article number	100549
Journal	Molecular Genetics and Metabolism Reports
Volume	22
DOIs	https://doi.org/10.1016/j.ymgmr.2019.100549
State	Published - Mar 2020

Bibliographical note

Funding Information:
Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme , and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme ; contract work for Shapiro Neuropsychology Consulting, LLC. King: Research support from Alexion Pharmaceuticals, Inc., Shire/Takeda, and Sanofi Genzyme, and contract work for Shapiro Neuropsychology Consulting, LLC. Shapiro: Partner, Shapiro Neuropsychology Consulting, LLC. Whitley: Research support from Shire /Takeda; consultant to Shire/Takeda. Muenzer: Consultant to BioMarin, Shire/Takeda, PTC Therapeutics, Green Cross, Sanofi Genzyme, Eloxx, Regenxbio, Denali Therapeutics, Sangamo and JCR Pharmaceuticals. Serves on advisory boards for BioMarin, Sanofi Genzyme, Green Cross, JCR Pharmaceuticals and Shire/Takeda. He is principal investigator for phase 1/2 and phase 2/3 trials that investigate intrathecal ERT for patients with neuronopathic Hunter syndrome, a phase 1/2 gene editing clinical trial for adults with Hunter syndrome and a phase 1/2 intravenous ERT clinical trial for MPS IIIA.

Funding Information:
Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme, and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme; contract work for Shapiro Neuropsychology Consulting, LLC.Whitley: Research support from Shire/Takeda; consultant to Shire/Takeda.This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc., Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644, and by NIH U54NS065768. Historic chart review and analysis was funded by NIH U54NS065768. The Lysosomal Disease Network (U54NS065768) is a part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, and the National Center for Advancing Translational Sciences. This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences, the National Institute of Neurological Disorders and Stroke, and the National Institute of Diabetes and Digestive and Kidney Diseases. Data curation was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society, Project Alive, MPS Superhero Foundation, the University of Minnesota Department of Pediatrics, and the University of Minnesota's Center for Neurobehavioral Development. None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication.We are grateful for the support and cooperation of these courageous children and their families. We thank Cure Sanfilippo Foundation, MPS Superhero Foundation, and Project Alive for consultation and direction regarding caregiver burden. We thank Brenda Diethelm-Okita and Ashley Schneider in the Lysosomal Disease Network office at the University of Minnesota for research and administrative support. We thank Sarah Lewis (HealthPartners, Minneapolis, MN) and Katherine Spurlock (West Virginia School of Osteopathic Medicine, Lewisburg, WV) for neuropsychological assistance.

Funding Information:
This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc. , Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644 , and by NIH U54NS065768 . Historic chart review and analysis was funded by NIH U54NS065768 . The Lysosomal Disease Network ( U54NS065768 ) is a part of the Rare Diseases Clinical Research Network , an initiative of the Office of Rare Diseases Research , and the National Center for Advancing Translational Sciences . This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences , the National Institute of Neurological Disorders and Stroke , and the National Institute of Diabetes and Digestive and Kidney Diseases . Data curation was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences , grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences . Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society , Project Alive , MPS Superhero Foundation , the University of Minnesota Department of Pediatrics , and the University of Minnesota's Center for Neurobehavioral Development . None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication.

Publisher Copyright:
© 2019 The Authors

Keywords

Behavioral decline
Hunter syndrome
Mucopolysaccharidosis II
Neurobehavioral symptoms
Neuronopathic phenotype

Access

10.1016/j.ymgmr.2019.100549

OpenUrl availability

Full text

Cite this

@article{42d29d07345144cc86d21f777f800067,

title = "The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome",

abstract = "In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.",

keywords = "Behavioral decline, Hunter syndrome, Mucopolysaccharidosis II, Neurobehavioral symptoms, Neuronopathic phenotype",

author = "Eisengart, {J. B.} and King, {K. E.} and Shapiro, {E. G.} and Whitley, {C. B.} and J. Muenzer",

note = "Funding Information: Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme , and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme ; contract work for Shapiro Neuropsychology Consulting, LLC. King: Research support from Alexion Pharmaceuticals, Inc., Shire/Takeda, and Sanofi Genzyme, and contract work for Shapiro Neuropsychology Consulting, LLC. Shapiro: Partner, Shapiro Neuropsychology Consulting, LLC. Whitley: Research support from Shire /Takeda; consultant to Shire/Takeda. Muenzer: Consultant to BioMarin, Shire/Takeda, PTC Therapeutics, Green Cross, Sanofi Genzyme, Eloxx, Regenxbio, Denali Therapeutics, Sangamo and JCR Pharmaceuticals. Serves on advisory boards for BioMarin, Sanofi Genzyme, Green Cross, JCR Pharmaceuticals and Shire/Takeda. He is principal investigator for phase 1/2 and phase 2/3 trials that investigate intrathecal ERT for patients with neuronopathic Hunter syndrome, a phase 1/2 gene editing clinical trial for adults with Hunter syndrome and a phase 1/2 intravenous ERT clinical trial for MPS IIIA. Funding Information: Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme, and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme; contract work for Shapiro Neuropsychology Consulting, LLC.Whitley: Research support from Shire/Takeda; consultant to Shire/Takeda.This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc., Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644, and by NIH U54NS065768. Historic chart review and analysis was funded by NIH U54NS065768. The Lysosomal Disease Network (U54NS065768) is a part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, and the National Center for Advancing Translational Sciences. This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences, the National Institute of Neurological Disorders and Stroke, and the National Institute of Diabetes and Digestive and Kidney Diseases. Data curation was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society, Project Alive, MPS Superhero Foundation, the University of Minnesota Department of Pediatrics, and the University of Minnesota's Center for Neurobehavioral Development. None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication.We are grateful for the support and cooperation of these courageous children and their families. We thank Cure Sanfilippo Foundation, MPS Superhero Foundation, and Project Alive for consultation and direction regarding caregiver burden. We thank Brenda Diethelm-Okita and Ashley Schneider in the Lysosomal Disease Network office at the University of Minnesota for research and administrative support. We thank Sarah Lewis (HealthPartners, Minneapolis, MN) and Katherine Spurlock (West Virginia School of Osteopathic Medicine, Lewisburg, WV) for neuropsychological assistance. Funding Information: This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc. , Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644 , and by NIH U54NS065768 . Historic chart review and analysis was funded by NIH U54NS065768 . The Lysosomal Disease Network ( U54NS065768 ) is a part of the Rare Diseases Clinical Research Network , an initiative of the Office of Rare Diseases Research , and the National Center for Advancing Translational Sciences . This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences , the National Institute of Neurological Disorders and Stroke , and the National Institute of Diabetes and Digestive and Kidney Diseases . Data curation was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences , grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences . Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society , Project Alive , MPS Superhero Foundation , the University of Minnesota Department of Pediatrics , and the University of Minnesota's Center for Neurobehavioral Development . None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = mar,

doi = "10.1016/j.ymgmr.2019.100549",

language = "English (US)",

volume = "22",

journal = "Molecular Genetics and Metabolism Reports",

issn = "2214-4269",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome

AU - Eisengart, J. B.

AU - King, K. E.

AU - Shapiro, E. G.

AU - Whitley, C. B.

AU - Muenzer, J.

N1 - Funding Information: Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme , and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme ; contract work for Shapiro Neuropsychology Consulting, LLC. King: Research support from Alexion Pharmaceuticals, Inc., Shire/Takeda, and Sanofi Genzyme, and contract work for Shapiro Neuropsychology Consulting, LLC. Shapiro: Partner, Shapiro Neuropsychology Consulting, LLC. Whitley: Research support from Shire /Takeda; consultant to Shire/Takeda. Muenzer: Consultant to BioMarin, Shire/Takeda, PTC Therapeutics, Green Cross, Sanofi Genzyme, Eloxx, Regenxbio, Denali Therapeutics, Sangamo and JCR Pharmaceuticals. Serves on advisory boards for BioMarin, Sanofi Genzyme, Green Cross, JCR Pharmaceuticals and Shire/Takeda. He is principal investigator for phase 1/2 and phase 2/3 trials that investigate intrathecal ERT for patients with neuronopathic Hunter syndrome, a phase 1/2 gene editing clinical trial for adults with Hunter syndrome and a phase 1/2 intravenous ERT clinical trial for MPS IIIA. Funding Information: Eisengart: Research support from Lysogene, Sangamo and Shire/Takeda; consultant to Denali Therapeutics, Regenxbio, Sangamo, Sanofi Genzyme, and Shire/Takeda; advisory boards for Amicus, bluebird bio, and Sanofi Genzyme; contract work for Shapiro Neuropsychology Consulting, LLC.Whitley: Research support from Shire/Takeda; consultant to Shire/Takeda.This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc., Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644, and by NIH U54NS065768. Historic chart review and analysis was funded by NIH U54NS065768. The Lysosomal Disease Network (U54NS065768) is a part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, and the National Center for Advancing Translational Sciences. This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences, the National Institute of Neurological Disorders and Stroke, and the National Institute of Diabetes and Digestive and Kidney Diseases. Data curation was supported by the National Institutes of Health's National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences. Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society, Project Alive, MPS Superhero Foundation, the University of Minnesota Department of Pediatrics, and the University of Minnesota's Center for Neurobehavioral Development. None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication.We are grateful for the support and cooperation of these courageous children and their families. We thank Cure Sanfilippo Foundation, MPS Superhero Foundation, and Project Alive for consultation and direction regarding caregiver burden. We thank Brenda Diethelm-Okita and Ashley Schneider in the Lysosomal Disease Network office at the University of Minnesota for research and administrative support. We thank Sarah Lewis (HealthPartners, Minneapolis, MN) and Katherine Spurlock (West Virginia School of Osteopathic Medicine, Lewisburg, WV) for neuropsychological assistance. Funding Information: This investigator-initiated research was supported by a grant from Shire Human Genetic Therapies Inc. , Lexington, MA, a member of the Takeda group of companies through # IIR-USA-001644 , and by NIH U54NS065768 . Historic chart review and analysis was funded by NIH U54NS065768 . The Lysosomal Disease Network ( U54NS065768 ) is a part of the Rare Diseases Clinical Research Network , an initiative of the Office of Rare Diseases Research , and the National Center for Advancing Translational Sciences . This consortium is funded through a collaboration between the National Center for Advancing Translational Sciences , the National Institute of Neurological Disorders and Stroke , and the National Institute of Diabetes and Digestive and Kidney Diseases . Data curation was supported by the National Institutes of Health 's National Center for Advancing Translational Sciences , grant UL1TR002494 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health's National Center for Advancing Translational Sciences . Resources for convening the caregiver advisory board and sharing of data were provided by Denali Therapeutics (South San Francisco, CA). The advisory board was facilitated by the first author (JBE). Infrastructure support was provided by the National MPS Society , Project Alive , MPS Superhero Foundation , the University of Minnesota Department of Pediatrics , and the University of Minnesota's Center for Neurobehavioral Development . None of the funding sources had any role in study design; collection, analysis and interpretation of data; writing of the manuscript; nor the decision to submit the article for publication. Publisher Copyright: © 2019 The Authors

PY - 2020/3

Y1 - 2020/3

N2 - In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.

AB - In neuronopathic Hunter syndrome, neurobehavioral symptoms are known to be serious but have been incompletely described. While families face significant stress stemming from this complex and far-reaching array of symptoms, neither caregiver burden nor the neurobehavioral symptoms have been measured comprehensively. We delineated these neurobehavioral characteristics and their impact on the caregiver using multiple approaches. Methods: As part of the initial phase of developing a Hunter-specific behavioral assessment tool, we used multiple methods to obtain data on patient behaviors and caregiver burden, with the intention of drafting item sets for the tool. We utilized 1) caregiver descriptions from focus groups and individual interviews, 2) observations from video-recorded play of affected children, 3) descriptions from historic chart review, 4) consultation with patient advocacy groups and international experts, 5) reports from a caregiver advisory board, and 6) literature review. Results: Neurobehavioral symptoms were diverse and categorized as focus/attention, impulsivity/heightened activity, sensation seeking, emotional/behavioral function, social interaction, and sleep. A significant reported challenge was susceptibility to misinterpretation of some behaviors as defiant or aggressive, particularly if physical. Caregiver burden involved social isolation, exhaustion, stress, and financial and vocational strain. These new descriptions will aid in developing quantitative measures of change in neurobehavioral symptoms and family burden. These descriptions will be the foundation of a neurobehavioral rating scale, which is very much needed to aid in patient management and assess interventions for individuals with neuronopathic Hunter syndrome.

KW - Behavioral decline

KW - Hunter syndrome

KW - Mucopolysaccharidosis II

KW - Neurobehavioral symptoms

KW - Neuronopathic phenotype

UR - http://www.scopus.com/inward/record.url?scp=85076632261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076632261&partnerID=8YFLogxK

U2 - 10.1016/j.ymgmr.2019.100549

DO - 10.1016/j.ymgmr.2019.100549

M3 - Article

C2 - 31890590

AN - SCOPUS:85076632261

SN - 2214-4269

VL - 22

JO - Molecular Genetics and Metabolism Reports

JF - Molecular Genetics and Metabolism Reports

M1 - 100549

ER -

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this